HK1250917A1 - 弥漫性神经纤维瘤用的外用药 - Google Patents

弥漫性神经纤维瘤用的外用药 Download PDF

Info

Publication number
HK1250917A1
HK1250917A1 HK18110308.6A HK18110308A HK1250917A1 HK 1250917 A1 HK1250917 A1 HK 1250917A1 HK 18110308 A HK18110308 A HK 18110308A HK 1250917 A1 HK1250917 A1 HK 1250917A1
Authority
HK
Hong Kong
Prior art keywords
sirolimus
diffuse
external preparation
neurofibroma
concentration
Prior art date
Application number
HK18110308.6A
Other languages
English (en)
Chinese (zh)
Inventor
金田真理
片山一朗
Original Assignee
国立大学法人大阪大学
國立大學法人大阪大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 国立大学法人大阪大学, 國立大學法人大阪大學 filed Critical 国立大学法人大阪大学
Publication of HK1250917A1 publication Critical patent/HK1250917A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK18110308.6A 2015-03-23 2016-03-09 弥漫性神经纤维瘤用的外用药 HK1250917A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015-059041 2015-03-23
JP2015059041A JP6541124B2 (ja) 2015-03-23 2015-03-23 びまん性神経線維腫用の外用薬
PCT/JP2016/057330 WO2016152519A1 (ja) 2015-03-23 2016-03-09 びまん性神経線維腫用の外用薬

Publications (1)

Publication Number Publication Date
HK1250917A1 true HK1250917A1 (zh) 2019-01-18

Family

ID=56978382

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18110308.6A HK1250917A1 (zh) 2015-03-23 2016-03-09 弥漫性神经纤维瘤用的外用药

Country Status (7)

Country Link
US (1) US10117857B2 (enExample)
EP (1) EP3275441B1 (enExample)
JP (1) JP6541124B2 (enExample)
CN (1) CN107708694A (enExample)
ES (1) ES2827953T3 (enExample)
HK (1) HK1250917A1 (enExample)
WO (1) WO2016152519A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020175131A1 (ja) * 2019-02-27 2020-09-03 国立大学法人大阪大学 脈管異常治療用外用剤
WO2021075328A1 (ja) * 2019-10-16 2021-04-22 国立大学法人大阪大学 てんかん治療用又は自閉症スペクトラム障害治療用外用剤
CN113332228B (zh) * 2021-04-29 2023-03-31 杭州中美华东制药有限公司 一种西罗莫司凝胶制剂
DE102023119976A1 (de) * 2023-07-27 2025-01-30 Nobelpharma Co., Ltd. Rapamycin-haltige pharmazeutische zusammensetzung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060160837A1 (en) * 2004-12-29 2006-07-20 The Brigham And Women's Hospital, Inc. Rapamycin compounds in the treatment of neurofibromatosis type 1
US8211875B2 (en) * 2005-02-02 2012-07-03 Nexgenix Pharmaceuticals Inc Local treatment of neurofibromas
AU2007211613C1 (en) 2006-02-02 2018-01-04 Novartis Ag Tuberous Sclerosis treatment
CN101827523A (zh) * 2007-08-16 2010-09-08 马库赛特公司 用于治疗眼部疾病或病症的制剂
AU2012211809A1 (en) * 2011-01-31 2013-09-05 Osaka University Externally-used drug for treating skin disorder and method for producing same

Also Published As

Publication number Publication date
EP3275441B1 (en) 2020-08-12
EP3275441A1 (en) 2018-01-31
EP3275441A4 (en) 2019-01-16
JP2016175884A (ja) 2016-10-06
JP6541124B2 (ja) 2019-07-10
ES2827953T3 (es) 2021-05-25
US20180110759A1 (en) 2018-04-26
WO2016152519A1 (ja) 2016-09-29
US10117857B2 (en) 2018-11-06
CN107708694A (zh) 2018-02-16

Similar Documents

Publication Publication Date Title
JP5652795B2 (ja) 皮膚疾患を処置するための外用薬およびその製造方法
EP2767292B1 (en) Sustained Local Anesthetic Composition Containing SAIB
EP4046625A1 (en) Use of acellular adipose tissue extract in promoting hair growth and retention
DE202008018583U1 (de) Arzneimittelgabe-Vorrichtung (Drug-Delivery-System) für die lokale Analgesie, Lokalanästhesie oder Nervenblockade
HK1250917A1 (zh) 弥漫性神经纤维瘤用的外用药
EP1883391B1 (en) Epidermal growth factor composition, a process therefor and its application
WO2017154675A1 (ja) ファブリー病処置剤、外用鎮痛剤、および発汗増進剤
AU2017267590A1 (en) Topical composition for the control of pain in animals
RU2280458C1 (ru) Противовоспалительная мазь
EP3932487A1 (en) External preparation for vascular abnormality treatment
CN110721152B (zh) 一种治疗动物皮肤寄生虫、真菌感染的缓释组合物
JP2022531154A (ja) 炎症により引き起こされる自己免疫性皮膚疾患を治療するための化合物及びその使用
CN106265112B (zh) 促进伤口愈合的药物或化妆用组合物
RU2794958C2 (ru) Композиция ранозаживляющего действия
KR101607229B1 (ko) 말기름을 함유하는 상처 치료용 조성물
JP7601398B2 (ja) てんかん治療用又は自閉症スペクトラム障害治療用外用剤
CN113289003A (zh) 一种干细胞因子组合物及其用途
RU2091074C1 (ru) Эмульсия для лечения метритов крупного рогатого скота (варианты)
Mirgorod et al. Grounds for selection of bases for preparing gel with phytos complex for treatment of skin diseases
CN117883363A (zh) 一种稳定的过氧化苯甲酰软膏得制备工艺及其应用
CN115364097A (zh) 一种含杂原子环丁烷取代基的吡啶酮衍生物的应用
HK1201437B (en) Sustained local anesthetic composition containing saib